LURASIDONE in the LONG-TERM TREATMENT of PATIENTS with BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY

Depression and Anxiety

Volumn 33, Issue 5, 2016, Pages 424-434

  Ketter, Terence A ^a   Sarma, Kaushik ^b,c   Silva, Robert ^b,c   Kroger, Hans ^b,c   Cucchiaro, Josephine ^b,c   Loebel, Antony ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c NONE   (United States)

Author keywords

antipsychotic agents; bipolar depression; bipolar disorder; depressive disorder; lithium; lurasidone; major depression; valproate

Indexed keywords

CHOLESTEROL; GLUCOSE; LITHIUM SALT; LURASIDONE; PLACEBO; TRIACYLGLYCEROL; VALPROIC ACID; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AKATHISIA; ALLERGIC REACTION; ANXIETY; APPENDICITIS; ARTICLE; BEDTIME DOSAGE; BIPOLAR DEPRESSION; BODY WEIGHT; BRADYKINESIA; COGWHEEL RIGIDITY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRACTURE; HEADACHE; HUMAN; HYPERSALIVATION; HYPERSOMNIA; HYPOKINESIA; INSOMNIA; LONG TERM CARE; LUMBAR SPINAL STENOSIS; MAJOR CLINICAL STUDY; MALE; MANIA; METABOLIC PARAMETERS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MUSCLE RIGIDITY; NAUSEA; OPEN STUDY; PANCREATITIS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; SEDATION; SKIN TUMOR; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; BIPOLAR DISORDER; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LITHIUM COMPOUNDS; LURASIDONE HYDROCHLORIDE; MALE; TIME; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84959304391     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22479     Document Type: Article

References (45)

1. Merikangas KR, Akiskal HS, Angst J, et al., Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
2. Judd LL, Akiskal HS, Schettler PJ, et al., The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
3. Kupka RW, Altshuler LL, Nolen WA, et al., Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007; 9: 531-535.
4. Kasper S, Calabrese JR, Johnson G, et al., International Consensus Group on the evidence-based pharmacological treatment of bipolar I and II depression. J Clin Psychiatry 2008; 69: 1632-1646.
5. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388.
6. Grunze H, Vieta E, Goodwin G, et al., The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of bipolar depression. World J Biol Psychiatry 2010; 11: 81-109.
7. Yatham LN, Kennedy SH, Parikh SV, et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update. Bipolar Disord 2013; 15: 1-44.
8. NICE Clinical Guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, London, UK, 2014. Available at: https://www.nice.org.uk/guidance/cg185. (accessed February 21, 2016).
9. Vieta E, Valentí M,. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 2013; 27: 515-529.
10. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM,. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003; 63: 2029-2050.
11. Calabrese JR, Keck PE, Jr., Macfadden W, et al., A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360.
12. Thase ME, Macfadden W, Weisler RH, et al., Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600-609
13. Tohen M, Vieta E, Calabrese J, et al., Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60: 1079-1088.
14. Thase ME, Jonas A, Khan A, et al., Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28: 13-20.
15. Lombardo I, Sachs G, Kolluri S, et al., Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012; 32: 470-478.
16. Sachs GS., Ice KS, P. B. Chappell PB, et al., Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1413-1422.
17. Weisler RH, Montgomery SA, Earley WR, et al., Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2012; 27: 27-39.
18. Vieta E, Suppes T, Eggens I, et al., Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263.
19. Suppes T, Vieta E, Liu S, et al., Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex. Am J Psychiatry 2009; 166: 476-488.
20. Suppes T, Vieta E, Gustafsson U, Ekholm B,. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety 2013; 30: 1089-1098.
21. Corya SA, Perlis RH, Keck PE, Jr., et al., A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006; 67: 798-806.
22. Brown E, Dunner DL, McElroy SL, et al., Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009; 12: 773-782.
23. Loebel A, Cucchiaro J, Silva R, et al., Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171: 160-168.
24. Loebel A, Cucchiaro J, Silva R, et al., Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171: 169-177.
25. Suppes T, Silva R, Kroger H, et al., Lurasidone Adjunctive Therapy With Lithium or Valproate for the Treatment Of Bipolar I Depression: A Randomized, Double Blind, Placebo-Controlled Study. Poster presentations at the annual meeting of the American College of Neuropsychopharmacology, December 8-12, 2013, Hollywood, FL 2013.
26. Montgomery SA, Åsberg M,. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 132: 382-389.
27. Young RC, Biggs JT, Ziegler VE, Meyer DA,. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
28. Barnes TR,. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
29. Simpson GN, Angus JWS,. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scand 1970; 212 (Suppl 44): 11-19.
30. Abnormal Involuntary Movement Scale (AIMS). In:, Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare; 1976: 534-537.
31. Posner K, Brown GK, Stanley B, et al., The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266-1277.
32. Hamilton M., The assessment of anxiety states by rating. British J Med Psychol 1959; 32: 50-55.
33. Sheehan DV,. The Anxiety Disease. New York: Bantam Books; 1983.
34. Endicott J, Nee J, Harrison W, Blumenthal R,. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-326.
35. Vieta E, Suppes T, Ekholm B, et al., Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord 2012; 142: 36-44.
36. Müller MJ, Himmerich H, Kienzle B, Szegedi A,. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 2003; 77: 255-260.
37. Kearns NP, Cruickshank CA, McGuigan KJ, et al., A comparison of depression rating scales. Br J Psychiatry 1982; 141: 45-49.
38. Lukasiewicz M, Gerard S, Besnard A, et al., Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res 2013; 22: 46-58.
39. Citrome L, Cucchiaro J, Sarma K, et al., Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012; 27: 165-176.
40. Loebel A, Cucchiaro J, Xu J, et al., Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res 2013; 147: 95-102.
41. Stahl SM, Cucchiaro J, Simonelli D, et al., Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry 2013; 74: 507-515.
42. Citrome L, Weiden PJ, McEvoy JP, et al., Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 2014: 330-339.
43. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ,. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009; 11: 657-662.
44. Vancampfort D, Vansteelandt K, Correll CU, et al., Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170: 265-274.
45. Calabrese JR, Bowden CL, Sachs G, et al., A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.